Download PDF
Semin intervent Radiol 2022; 39(06): 587-590
DOI: 10.1055/s-0042-1759703
How I Do It

Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!

Islam A. S. Elhelf
1   Interventional Radiology, Department of Radiology, Medical College of Georgia, Augusta University, Augusta, Georgia
2   Nuclear Medicine, Department of Radiology, Medical College of Georgia, Augusta University, Augusta, Georgia
,
Michael Clemenshaw
2   Nuclear Medicine, Department of Radiology, Medical College of Georgia, Augusta University, Augusta, Georgia
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

In 2018, the Food and Drug Administration (FDA) approved lutetium-177 (177Lu) DOTATATE (LUTATHERA, Advanced Accelerator Applications [Novartis]) for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Since then, 177Lu DOTATATE has been increasingly used as a treatment option for NETs. Less than 5 years later, in March 2022, 177Lu vipivotide tetraxetan (PLUVICTO, Advanced Accelerator Applications) received FDA approval for the treatment of prostate-specific membrane antigen-positive castration-resistant metastatic prostate cancer. Both drugs are excellent examples of viable radiotheranostic therapies. As more radiotheranostic agents and applications get adopted in clinical practice, interventional radiologists are likely to get exposed to this field in a way or another. In this article, we discuss the fundamentals of radiotheranostic therapy and explore the expanding role interventional radiology (IR) is expected to play as an essential partner in modern oncology practice.



Publication History

Article published online:
20 December 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Fahey FH, Grant FD, Thrall JH. Saul Hertz, MD, and the birth of radionuclide therapy. EJNMMI Phys 2017; 4 (01) 15
    CrossrefPubMedGoogle Scholar
  • 2 Goldsmith SJ. Targeted radionuclide therapy: a historical and personal review. Semin Nucl Med 2020; 50 (01) 87-97
    CrossrefPubMedGoogle Scholar
  • 3 Herrmann K, Schwaiger M, Lewis JS. et al. Radiotheranostics: a roadmap for future development. Lancet Oncol 2020; 21 (03) e146-e156
    CrossrefPubMedGoogle Scholar
  • 4 Hennrich U, Kopka K. Lutathera®: the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel) 2019; 12 (03) 114
    CrossrefPubMedGoogle Scholar
  • 5 Hope TA, Abbott A, Colucci K. et al. NANETS/SNMMI procedure standard for somatostatin receptor–based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med 2019; 60 (07) 937-943
    CrossrefPubMedGoogle Scholar
  • 6 Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. 111In-pentetreotide scintigraphy versus 68Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden. J Nucl Med 2019; 60 (09) 1266-1269
    CrossrefPubMedGoogle Scholar
  • 7 Ramage JK, Ahmed A, Ardill J. et al; UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61 (01) 6-32
    CrossrefPubMedGoogle Scholar
  • 8 Strosberg JR, El-Haddad G, Al-Toubah T. et al. Radioembolization versus bland or chemoembolization for liver-dominant neuroendocrine tumors: Is it an either/or question?. J Nucl Med 2021; 62: 1669-1671
    CrossrefPubMedGoogle Scholar
  • 9 Cavalcoli F, Rausa E, Conte D, Nicolini AF, Massironi S. Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?. World J Gastroenterol 2017; 23 (15) 2640-2650
    CrossrefPubMedGoogle Scholar
  • 10 Strosberg J, El-Haddad G, Wolin E. et al; NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017; 376 (02) 125-135
    CrossrefPubMedGoogle Scholar
  • 11 Cornelis FH, Durack JC, Morris MJ, Scher HI, Solomon SB. Effective prostate-specific membrane antigen-based 18F-DCFPyL-guided cryoablation of a single positive site in a patient believed to be more metastatic on 11C-choline PET/CT. Clin Nucl Med 2017; 42 (12) e516-e518
    CrossrefPubMedGoogle Scholar
  • 12 Lohaus F, Zöphel K, Löck S. et al. Can local ablative radiotherapy revert castration-resistant prostate cancer to an earlier stage of disease?. Eur Urol 2019; 75 (04) 548-551
    CrossrefPubMedGoogle Scholar
  • 13 Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials 2020; 21 (01) 141
    CrossrefPubMedGoogle Scholar
  • 14 Sayman HB, Gulsen F, Sager S. et al. Selective intra-arterial lutetium-177-labeled prostate-specific membrane antigen therapy for castration-resistant prostate cancer: initial results. J Vasc Interv Radiol 2022; 33 (03) 342-345
    CrossrefPubMedGoogle Scholar
  • 15 Vonken EPA, Bruijnen RCG, Snijders TJ. et al. Intraarterial administration boosts 177Lu-HA-DOTATATE accumulation in salvage meningioma patients. J Nucl Med 2022; 63 (03) 406-409
    CrossrefPubMedGoogle Scholar
  • 16 International Medical Graduates Alternate Pathway. American Board of Radiology Website. Accessed September 12, 2022 at: https://www.theabr.org/diagnostic-radiology/initial-certification/alternate-pathways/international-medical-graduates
    PubMed